Literature DB >> 25804612

High-density lipoprotein-cholesterol, daily estradiol and progesterone, and mammographic density phenotypes in premenopausal women.

Vidar G Flote1, Hanne Frydenberg2, Giske Ursin3, Anita Iversen4, Morten W Fagerland5, Peter T Ellison6, Erik A Wist2, Thore Egeland7, Tom Wilsgaard4, Anne McTiernan8, Anne-Sofie Furberg4, Inger Thune9.   

Abstract

High-density lipoprotein-cholesterol (HDL-C) may influence the proliferation of breast tumor cells, but it is unclear whether low HDL-C levels, alone or in combination with cyclic estrogen and progesterone, are associated with mammographic density, a strong predictor of breast cancer development. Fasting morning serum concentrations of HDL-C were assessed in 202 premenopausal women, 25 to 35 years of age, participating in the Norwegian Energy Balance and Breast Cancer Aspects (EBBA) I study. Estrogen and progesterone were measured both in serum, and daily in saliva, throughout an entire menstrual cycle. Absolute and percent mammographic density was assessed by a computer-assisted method (Madena), from digitized mammograms (days 7-12). Multivariable models were used to study the associations between HDL-C, estrogen and progesterone, and mammographic density phenotypes. We observed a positive association between HDL-C and percent mammographic density after adjustments (P = 0.030). When combining HDL-C, estradiol, and progesterone, we observed among women with low HDL-C (<1.39 mmol/L), a linear association between salivary 17β-estradiol, progesterone, and percent and absolute mammographic density. Furthermore, in women with low HDL-C, each one SD increase of salivary mid-menstrual 17β-estradiol was associated with an OR of 4.12 (95% confidence intervals; CI, 1.30-13.0) of having above-median percent (28.5%), and an OR of 2.5 (95% CI, 1.13-5.50) of having above-median absolute mammographic density (32.4 cm(2)). On the basis of plausible biologic mechanisms linking HDL-C to breast cancer development, our findings suggest a role of HDL-C, alone or in combination with estrogen, in breast cancer development. However, our small hypothesis generating study requires confirmation in larger studies. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25804612     DOI: 10.1158/1940-6207.CAPR-14-0267

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  8 in total

1.  The metabolic syndrome and mammographic breast density in a racially diverse and predominantly immigrant sample of women.

Authors:  Parisa Tehranifar; Angeline Protacio; Karen M Schmitt; Elise Desperito; Sabine Oskar; Alan J Potter; Natalie J Engmann; Mary Beth Terry
Journal:  Cancer Causes Control       Date:  2015-07-14       Impact factor: 2.506

2.  Circulating lipids, mammographic density, and risk of breast cancer in the Nurses' Health Study and Nurses' Health Study II.

Authors:  Sarah A Lucht; A Heather Eliassen; Kimberly A Bertrand; Thomas P Ahern; Signe Borgquist; Bernard Rosner; Susan E Hankinson; Rulla M Tamimi
Journal:  Cancer Causes Control       Date:  2019-07-01       Impact factor: 2.506

3.  Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes.

Authors:  F N Fjeldheim; H Frydenberg; V G Flote; A McTiernan; A-S Furberg; P T Ellison; E S Barrett; T Wilsgaard; G Jasienska; G Ursin; E A Wist; I Thune
Journal:  BMC Cancer       Date:  2016-10-07       Impact factor: 4.430

4.  ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer.

Authors:  Lídia Cedó; Annabel García-León; Lucía Baila-Rueda; David Santos; Victor Grijalva; Melanie Raquel Martínez-Cignoni; José M Carbó; Jari Metso; Laura López-Vilaró; Antonio Zorzano; Annabel F Valledor; Ana Cenarro; Matti Jauhiainen; Enrique Lerma; Alan M Fogelman; Srinivasa T Reddy; Joan Carles Escolà-Gil; Francisco Blanco-Vaca
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

Review 5.  Influence of cholesterol on cancer progression and therapy.

Authors:  Shyamananda Singh Mayengbam; Abhijeet Singh; Ajay D Pillai; Manoj Kumar Bhat
Journal:  Transl Oncol       Date:  2021-03-19       Impact factor: 4.243

6.  Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer.

Authors:  Vidar G Flote; Riyas Vettukattil; Tone F Bathen; Thore Egeland; Anne McTiernan; Hanne Frydenberg; Anders Husøy; Sissi E Finstad; Jon Lømo; Øystein Garred; Ellen Schlichting; Erik A Wist; Inger Thune
Journal:  Lipids Health Dis       Date:  2016-03-12       Impact factor: 3.876

7.  Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.

Authors:  Trygve Lofterød; Elin S Mortensen; Hawa Nalwoga; Tom Wilsgaard; Hanne Frydenberg; Terje Risberg; Anne Elise Eggen; Anne McTiernan; Sura Aziz; Erik A Wist; Andreas Stensvold; Jon B Reitan; Lars A Akslen; Inger Thune
Journal:  BMC Cancer       Date:  2018-06-15       Impact factor: 4.430

8.  Relationship of Serum Progesterone and Progesterone Metabolites with Mammographic Breast Density and Terminal Ductal Lobular Unit Involution among Women Undergoing Diagnostic Breast Biopsy.

Authors:  Manila Hada; Hannah Oh; Shaoqi Fan; Roni T Falk; Berta Geller; Pamela Vacek; Donald Weaver; John Shepherd; Jeff Wang; Bo Fan; Sally Herschorn; Louise A Brinton; Xia Xu; Mark E Sherman; Britton Trabert; Gretchen L Gierach
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.